GlassScriptPhysician profile
Nazmine Deol
NPI 1932767761
$2,840.77
in general payments reported to CMS, 2019-2025
34 companies · $750 in 2025
The $750 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.84 · 2020: $120 · 2021: $420 · 2022: $28.75 · 2023: $1,084 · 2024: $377 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,210.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $475.72 | 2023-2025 | Nuzyra |
| Pfizer INC. | $330.06 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $215.81 | 2020-2021 | |
| Mimedx Group, INC. | $187.23 | 2024-2025 | |
| Stryker Corporation | $169.28 | 2025 | Limflow System |
| Integra Lifesciences Corporation | $163.73 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medtronic, INC. | $133.46 | 2023 | Hawkone |
| Amgen INC. | $126.17 | 2023-2025 | Evenity, Krystexxa, Otezla |
| Horizon Therapeutics Plc | $125.00 | 2023 | Krystexxa |
| Biotissue Holdings INC. | $114.71 | 2021 | |
| Organogenesis INC. | $114.51 | 2021-2024 | |
| Melinta Therapeutics, LLC | $111.14 | 2023 | Kimyrsa |
| Neurocrine Biosciences, INC. | $102.08 | 2021 | |
| Dexcom, INC. | $50.82 | 2023-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $39.67 | 2023-2025 | Ozempic, Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $31.25 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $31.08 | 2023 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.60 | 2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $24.98 | 2022 | |
| Inspire Medical Systems, INC. | $22.18 | 2025 | Inspire |
| Orthofix Medical, INC. | $21.25 | 2025 | Physio-Stim |
| Bayer Healthcare Pharmaceuticals INC. | $20.69 | 2023 | |
| Reprise Biomedical, INC. | $20.25 | 2024 | Miro3d |
| Abbvie INC. | $20.25 | 2023 | Dalvance |
| Abbott Laboratories | $19.72 | 2023 | Freestyle Libre 3 |
| Organon LLC | $19.61 | 2023 | Nexplanon |
| Smith+Nephew, INC. | $19.58 | 2025 | Grafix Pl |
| Mayne Pharma Commercial LLC | $18.33 | 2023 | |
| Nevro Corp. | $17.97 | 2023 | Senza |
| Kowa Pharmaceuticals America, INC. | $17.01 | 2023 | Seglentis |
| Lilly USA, LLC | $16.67 | 2024 | Mounjaro |
| Myovant Sciences INC. | $15.99 | 2021 | |
| Scpharmaceuticals INC. | $13.20 | 2023 | |
| Microaire Surgical Instruments LLC | $3.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nazmine Deol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.